Neoplasm
Disease2 papers
- Humans1
- Cells1
Trial sponsors
Company4 trialsPhase 4171 people
Novartis Pharmaceuticals Corporation
Company3 trialsPhase 4117 people
Company2 trialsPhase 3306 people
Johnson and Johnson Pharmaceutical Research and Development
Company3 trialsPhase 2242 people
Company1 trialPhase 1/2301 people
Company2 trialsPhase 1910 people
Company2 trialsPhase 183 people
Company2 trialsPhase 153 people
Latest
13SASP factors drive growth of altered cancer cells in culture
Using a microarray platform, researchers identified shared growth drivers in breast and lung cancer cells that required cellular alterations to…Using a microarray platform, researchers identified shared growth drivers in breast and lung cancer cells that required cellular alterations to promote proliferation.
Causes of life expectancy extension in Singapore, 2004–2022: Bridging past and present
Incidental detection of JAK2 V617F mutations in next-generation sequencing analysis of solid tumours: a guide to further workup
Temporal Trends and Disparities in Malignant Brain Neoplasms and Cardiac Arrest- Associated Mortality in the United States, 1999-2024: A Retrospective Analysis
Vitamin D status and colorectal neoplasm risk in Lynch syndrome
Germline HRD limits therapy-driven clonal hematopoiesis
Serial blood samples revealed carboplatin and PARP inhibitors expand DNA damage response clones, though germline homologous recombination deficiency…Serial blood samples revealed carboplatin and PARP inhibitors expand DNA damage response clones, though germline homologous recombination deficiency reduces this growth.